<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04097574</url>
  </required_header>
  <id_info>
    <org_study_id>NPO-13-01/ED-01</org_study_id>
    <nct_id>NCT04097574</nct_id>
  </id_info>
  <brief_title>Study of NPO-13 During Colonoscopy</brief_title>
  <official_title>Phase II Study of NPO-13 in Patients Undergoing Colonoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nihon Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nihon Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the safety, efficacy and dose-response of NPO-13 in subjects with
      moderate to severe colonic spasm during colonoscopy. An intraluminal spraying of NPO-13 dosed
      up to twice into ascending or sigmoid colon. The colonic spasm will be assessed by an
      independent committee using recorded video images. The study consists of a screening visit
      window, 1-day treatment phase and 1-week follow-up phase.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2019</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of No or Mild colonic spasm at the all sites of NPO-13 treatment</measure>
    <time_frame>3 minutes</time_frame>
    <description>The primary endpoint will be evaluated by third-party organization, using a four-grade scale: 1, No; 2, Mild; 3, Moderate; 4, Severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of No or Mild colonic spasm at the each site of NPO-13 treatment</measure>
    <time_frame>3 minutes</time_frame>
    <description>The secondary endpoint will be evaluated by third-party organization, using a four-grade scale: 1, No; 2, Mild; 3, Moderate; 4, Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in colonic spasm before and after treatment of NPO-13 treatment</measure>
    <time_frame>3 minutes</time_frame>
    <description>The evaluated colonic spasm grades will be converted into a numeric score, and difference between paired mean scores (before and after application, or 0.8% NPO-13, 1.6% NPO-13 and placebo) will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to effect</measure>
    <time_frame>3 minutes</time_frame>
    <description>The onset of anti-spasmodic effect is the interval from the spray to the disappearance of the spasm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difficulty of endoscopic observation</measure>
    <time_frame>3 minutes</time_frame>
    <description>The proportion of subjects in whom intracolonic examination will be evaluated by the investigator to be &quot;Very easy&quot; or &quot;Easy&quot;., using a four-grade scale: 1, Very easy; 2, Easy; 3, Difficult; 4, Hard.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and Adverse drug reactions</measure>
    <time_frame>7 Â± 3 days</time_frame>
    <description>The subjects will be observed for 7 days after colonoscopy, and all adverse events and adverse drug reactions will be recorded and compared with the placebo group.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Bowel Disease</condition>
  <arm_group>
    <arm_group_label>NPO-13 0.8%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPO-13 1.6%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPO-13 0%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPO-13: l-menthol</intervention_name>
    <description>20 mL/site</description>
    <arm_group_label>NPO-13 0%</arm_group_label>
    <arm_group_label>NPO-13 0.8%</arm_group_label>
    <arm_group_label>NPO-13 1.6%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who are between 20 and 85 years at the time of consent

          2. Patients who need colonoscopy

        Exclusion Criteria:

          1. Patients with a history of abdominal surgical treatment (including the laparoscopic
             surgery) including the gynecology operation

          2. Patients with contraindication to colonoscopy including the paralytic ileus

          3. Patients with a history of shock or hypersensitivity to l-menthol or peppermint oil
             (mint oil)

          4. Patient with contraindication to bowel cleansing preparation

          5. Patient with contraindication to pain medicine and sedative medicine

          6. Patient with contraindication to butylscopolamine bromide and glucagon

          7. Patients on cancer treatment (chemotherapy or radiotherapy)

          8. Patient with active inflammatory bowel disease or infectious enteritis

          9. Patients who need sedative in colonoscopy

         10. Patients who receives a therapeutic colonoscopy

         11. Pregnant or lactating women, women of childbearing potential, or women who plan to
             become pregnant during the study

         12. Patients who have received other investigational drugs within four months before
             consent or who are participating in other clinical studies

         13. Patients otherwise ineligible for participation in the study in the investigator's or
             coinvestigator's opinion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hisatsugu Asada</last_name>
    <role>Study Chair</role>
    <affiliation>Nihon Pharmaceutical Co., Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hisatsugu Asada</last_name>
    <phone>+81-3-5148-7570</phone>
    <email>kaihatsu@nihon-pharm.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>NPO-13 Trial Site 11</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NPO-13 Trial Site 12</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NPO-13 Trial Site 2</name>
      <address>
        <city>Maebashi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NPO-13 Trial Site 5</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NPO-13 Trial Site 6</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NPO-13 Trial Site 1</name>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NPO-13 Trial Site 4</name>
      <address>
        <city>Minato</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NPO-13 Trial Site 3</name>
      <address>
        <city>Shinjuku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NPO-13 Trial Site 9</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NPO-13 Trial Site 13</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NPO-13 Trial Site 10</name>
      <address>
        <city>Kochi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NPO-13 Trial Site 7</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NPO-13 Trial Site 8</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 20, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>September 19, 2019</last_update_submitted>
  <last_update_submitted_qc>September 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

